Topics
Gliomas | Treatment | Clinical trials | Overview
Home > Publications > Topics > Gliomas > Treatment > Clinical trials > Overview
Shikalov A, Koman I, Kogan NM.
Targeted
Glioma Therapy-Clinical Trials and Future
Directions.
Pharmaceutics.
2024 Jan 11;16(1):100. doi:
10.3390/pharmaceutics16010100. PMID:
38258110. Review. ˍ
Zugman M, Haslam A, Prasad V.
INDIGO:
Example of inappropriate crossover and why PFS cannot be the
primary outcome in gliomas.
J
Cancer Policy. 2024 Apr 6;40:100476. doi:
10.1016/j.jcpo.2024.100476. PMID:
38588795. Comment˰ ˍ
RELATED
ARTICLE
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat
M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP,
Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa
Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la
Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L,
Hassan I, Wen PY, Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ